Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2006; 12(21): 3306-3313
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3306
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3306
Antibiotics | Probiotics |
Eradication of bacterial antigenic triggers | Inhibition of pathogenic enteric bacteria by: |
Elimination of bacterial overgrowth | decreasing luminal pH |
Reduction of pro-inflammatory bacterial toxins | secretion of bacteriocidal proteins |
Potential immunosuppressive properties of antibiotics | resisting colonization |
blocking epithelial binding | |
Improvement in epithelial and mucosal barrier function by: | |
production of short-chain fatty acids | |
enhancing mucus production | |
increasing barrier integrity | |
Alteration of immunoregulation by: | |
increasing interleukin-10 and TGFβ, and decreasing TNF levels | |
increasing IgA production |
- Citation: Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 2006; 12(21): 3306-3313
- URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3306.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3306